ClinicalTrials.gg
CompletedNCT00428948TEMPO3:4Updated Jul 2, 2017Results posted

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 3 interventional study of Tolvaptan and Placebo in Polycystic Kidney Disease, Autosomal Dominant, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 133 sites in 15 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,445
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
2nd of 18
1,445 · median 91
Started
2007
the only one that year
Phase 3
8 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 8 in phase 3, and was the 2nd registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.

Read the detailed description

This study evaluated whether or not tolvaptan is potentially beneficial, while maintaining an adequate safety profile, by reducing the rate of total kidney volume increase, while impacting the onset, severity, and progression of other important consequences of ADPKD.

During the 3-week titration phase, tolvaptan or placebo was titrated in weekly intervals from lowest to highest tolerated levels given in split-dose regimens of 45/15 mg, 60/30 mg and 90/30 mg orally upon awakening and approximately 9 hours later. As soon as a subject could not tolerate a given dose, the titration phase was over and the maintenance phase began at the dose level tolerated. The maintenance phase lasted to Month 36. Subjects were able to titrate down at any point during the study. Subjects were able to titrate up during the maintenance phase with Medical Monitor approval.

03

Conditions studied

  • Polycystic Kidney Disease, Autosomal Dominant

Keywords

  • ADPKD
  • Polycystic
  • kidney
  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Legal adult age and able to give .
  • Adult subjects with a diagnosis of ADPKD. A diagnosis of ADPKD (age 18 or 20-50) required several cysts in each kidney (3 if by sonography, 5 if by CT or MRI) in those with a family history of ADPKD and 10 cysts (by any radiologic method) in each kidney and exclusion of other cystic kidney diseases if there was no family history.
  • Willingness to comply with reproductive precautions, if female.
  • Estimated ≥ 60 mL/min. Estimated from serum creatinine during screening using Cockcroft-Gault with correction for gender and race, where possible.
  • Rapidly progressive kidney growth (total volume ≥ 750 cc) by magnetic resonance imaging (MRI) at randomization.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to tolvaptan or other experimental PKD therapies.
  • Currently taking medication for purpose of affecting PKD cysts.
  • Women who are breast feeding and females of who are not using acceptable methods.
  • In the opinion of the study investigator or sponsor may present a safety risk or confound study objectives.
  • Patients who are unlikely to adequately comply with study procedures.
  • Patients having to MRI.
  • Patients taking medications or having any illnesses likely to affect ADPKD outcomes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,445 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.

    Drug: Tolvaptan

  • Placebo comparator
    Placebo

    Participants received placebo (upon awakening and 9 hours later) orally for 36 months.

    Drug: Placebo

Interventions

  • Tolvaptan was supplied as tablets.

    Also known as: OPC-41061, OPC-156

  • DrugPlacebo

    Placebo was supplied as tablets.

06

What researchers measure

Primary outcomes

  1. Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36

    Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, blinded radiologists used proprietary software to measure the volume of both kidneys.

    Time frame: Baseline to Month 36

Secondary outcomes

  1. Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36

    These ADPKD events in the key secondary Outcome Measure were selected on the basis of their potential relationship to progressing cystogenesis. Reducing the rate of cyst development and expansion would likely slow the progression of ADPKD. The 4 events were: (1) Onset or progression of hypertension (someone is hypertensive if they have \> 139 mmHg systolic blood pressure \[BP\], \> 89 mmHg diastolic BP, or if they are taking antihypertensive medication at any BP level); (2) severe renal pain requiring medical intervention; (3) worsening albuminuria (by category, see below); and (4) worsening renal function, defined as a 25% decrease in 1/serum creatinine from Baseline. Albuminuria was assessed using spot urine albumin/creatinine ratio measurements (all measurements in mg/mmol). Categories included normal (\< 2.8 female or \< 2.0 male), microalbuminuria (2.8-28 female or 2.0-20 male), and overt proteinuria (\> 28 female or \> 20 male.

    Time frame: Baseline to Month 36

  2. Change in Renal Function Per Year From Week 3 to Month 36

    Renal function was assessed using serum creatinine measurements and was estimated using 1/serum creatinine. The formula for 1/serum creatinine is: 1/Pcr, where Pcr = serum creatinine concentration (mg/dL). The change in renal function per year was based on the slope of change, obtained by regressing renal function data against time by subject.

    Time frame: Week 3 to Month 36

  3. Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36

    For participants who were non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) at baseline, mean arterial blood pressure was measured at scheduled clinic visits up to the point of exposure to antihypertensive therapy for any reason. The change in mean arterial blood pressure per year was based on the slope of blood pressure, obtained by regressing blood pressure against time by subject.

    Time frame: Baseline to Month 36

  4. Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36

    Change from baseline in renal pain was assessed by a 0 to 10 pain scale as average area under the concentration-time curve (AUC) between baseline and the last trial visit or the last visit prior to initiating medical (eg, narcotic or anti-nociceptives \[eg, tricyclic antidepressants\]) or surgical therapy for pain. In the pain scale, score 0 represented no pain at all and score 10 represented the worst pain. A negative change score indicates less pain. AUC of renal pain was derived from renal pain scores within treatment period and was calculated using the trapezoidal rule, by dividing the number of days between the first and last assessment.

    Time frame: At screening, Baseline, Day 1, every 4 months up to month 36/early tremination (ET), follow-up visit 1 and 2

  5. Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36

    A hypertensive event was defined as a change from non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) status to 1 of 3 conditions: (1) High pre-hypertensive (systolic BP \[sBP\] \> 129 mmHg and/or diastolic BP \[dBP\] \> 84 mmHg), (2) hypertensive (sBP \> 139 mmHg and/or dBP \> 89 mmHg), or (3) requiring antihypertensive therapy.

    Time frame: Baseline to Month 36

  6. Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36

    Time frame: Baseline to Month 36

07

Results

Posted Jul 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneTolvaptanPlacebo
Started961484
Received treatment961483
Completed740417
Not completed22167
Withdrew: Lost to follow-up158
Withdrew: Adverse event14824
Withdrew: Subject met withdrawal criteria40
Withdrew: Investigator withdrew subject34
Withdrew: Subject withdrew consent5030
Withdrew: Protocol deviation11

Outcome measures

PrimaryPercentage Change Per Year in Total Kidney Volume From Baseline to Month 36

Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, blinded radiologists used proprietary software to measure the volume of both kidneys.

Time frame:
Baseline to Month 36
Reported as:
Mean · Percentage change per year
Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36
Percentage change per yearTolvaptanPlacebo
Percentage Change Per Year in Total Kidney Volume From Baseline to Month 362.777 ± 5.6595.608 ± 5.330
Statistical analysis
  • Tolvaptan vs Placebo · Linear mixed model · p = <0.0001 · Mean difference (final values): -2.708 · 95% CI -3.269 to -2.147The variance of the random effect intercept was zero and resulted in a non-positive, definite variance-covariance matrix for the random effects.
SecondaryNumber of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36

These ADPKD events in the key secondary Outcome Measure were selected on the basis of their potential relationship to progressing cystogenesis. Reducing the rate of cyst development and expansion would likely slow the progression of ADPKD. The 4 events were: (1) Onset or progression of hypertension (someone is hypertensive if they have \> 139 mmHg systolic blood pressure \[BP\], \> 89 mmHg diastolic BP, or if they are taking antihypertensive medication at any BP level); (2) severe renal pain requiring medical intervention; (3) worsening albuminuria (by category, see below); and (4) worsening renal function, defined as a 25% decrease in 1/serum creatinine from Baseline. Albuminuria was assessed using spot urine albumin/creatinine ratio measurements (all measurements in mg/mmol). Categories included normal (\< 2.8 female or \< 2.0 male), microalbuminuria (2.8-28 female or 2.0-20 male), and overt proteinuria (\> 28 female or \> 20 male.

Time frame:
Baseline to Month 36
Reported as:
Number · Events/100 follow-up years
Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36
Events/100 follow-up yearsTolvaptanPlacebo
Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 3643.9450.04
Statistical analysis
  • Tolvaptan vs Placebo · Recurrent event analysis · p = 0.0095 · Hazard ratio (hr): 0.865 · 95% CI 0.775 to 0.965Tolvaptan divided by placebo.
SecondaryChange in Renal Function Per Year From Week 3 to Month 36

Renal function was assessed using serum creatinine measurements and was estimated using 1/serum creatinine. The formula for 1/serum creatinine is: 1/Pcr, where Pcr = serum creatinine concentration (mg/dL). The change in renal function per year was based on the slope of change, obtained by regressing renal function data against time by subject.

Time frame:
Week 3 to Month 36
Reported as:
Mean · (mg/mL)^-1 per year
Change in Renal Function Per Year From Week 3 to Month 36
(mg/mL)^-1 per yearTolvaptanPlacebo
Change in Renal Function Per Year From Week 3 to Month 36-2.555 ± 9.767-3.682 ± 6.361
Statistical analysis
  • Tolvaptan vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in slope: 0.977 · 95% CI 0.597 to 1.357Derived from testing the time treatment interaction using linear mixed model in which both intercept and slope are fixed and random effects.
SecondaryChange in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36

For participants who were non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) at baseline, mean arterial blood pressure was measured at scheduled clinic visits up to the point of exposure to antihypertensive therapy for any reason. The change in mean arterial blood pressure per year was based on the slope of blood pressure, obtained by regressing blood pressure against time by subject.

Time frame:
Baseline to Month 36
Reported as:
Mean · mmHg
Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36
mmHgTolvaptanPlacebo
Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 362.561 ± 9.7982.592 ± 7.095
Statistical analysis
  • Tolvaptan vs Placebo · Mixed Models Analysis · p = 0.5520 · Difference in slope: -0.246 · 95% CI -1.059 to 0.566Placebo minus tolvaptan.
SecondaryArea Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36

Change from baseline in renal pain was assessed by a 0 to 10 pain scale as average area under the concentration-time curve (AUC) between baseline and the last trial visit or the last visit prior to initiating medical (eg, narcotic or anti-nociceptives \[eg, tricyclic antidepressants\]) or surgical therapy for pain. In the pain scale, score 0 represented no pain at all and score 10 represented the worst pain. A negative change score indicates less pain. AUC of renal pain was derived from renal pain scores within treatment period and was calculated using the trapezoidal rule, by dividing the number of days between the first and last assessment.

Time frame:
At screening, Baseline, Day 1, every 4 months up to month 36/early tremination (ET), follow-up visit 1 and 2
Reported as:
Mean · units on a scale
Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36
units on a scaleTolvaptanPlacebo
Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36-0.00 ± 1.290.08 ± 1.43
Statistical analysis
  • Tolvaptan vs Placebo · ANCOVA · p = 0.1604 · Mean difference (final values): -0.08 · 95% CI -0.20 to 0.03Derived from ANCOVA with factors of treatment and baseline stratification factor interaction and covariate renal pain baseline.
SecondaryNumber of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36

A hypertensive event was defined as a change from non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) status to 1 of 3 conditions: (1) High pre-hypertensive (systolic BP \[sBP\] \> 129 mmHg and/or diastolic BP \[dBP\] \> 84 mmHg), (2) hypertensive (sBP \> 139 mmHg and/or dBP \> 89 mmHg), or (3) requiring antihypertensive therapy.

Time frame:
Baseline to Month 36
Reported as:
Number · Events/100 follow-up years
Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36
Events/100 follow-up yearsTolvaptanPlacebo
Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 3631.8029.60
Statistical analysis
  • Tolvaptan vs Placebo · Recurrent event analysis · p = 0.9704 · Hazard ratio (hr): 0.996 · 95% CI 0.805 to 1.233Derived from rate and mean model of time to recurrent event analysis with factor treatment.
SecondaryPercentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36
Time frame:
Baseline to Month 36
Reported as:
Number · Percentage of participants
Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36
Percentage of participantsTolvaptanPlacebo
Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 366.245.62
Statistical analysis
  • Tolvaptan vs Placebo · Cochran-Mantel-Haenszel · p = 0.7532 · Risk ratio (rr): 1.100 · 95% CI 0.602 to 2.017Tolvaptan divided by placebo.

Adverse events

Collected over Adverse events were collected from the time of signing the informed consent, throughout the 3 year treatment period and up to 42 days after the last dose of study medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan—177/961 (18.4%)793/961 (82.5%)
Placebo—95/483 (19.7%)372/483 (77%)
Most frequent serious events
Showing 10 of 211
Most frequent serious events
EventTolvaptanPlacebo
PyelonephritisInfections and infestations5/9615/483
Alanine aminotransferase increasedInvestigations9/9612/483
Aspartate aminotransferase increasedInvestigations9/9612/483
Chest painGeneral disorders8/9612/483
AppendicitisInfections and infestations1/9614/483
Renal cyst infectionInfections and infestations6/9614/483
Renal cyst haemorrhageRenal and urinary disorders3/9614/483
Renal painRenal and urinary disorders1/9614/483
Urinary tract infectionInfections and infestations1/9613/483
NephrolithiasisRenal and urinary disorders2/9613/483
Most frequent other events
Showing 10 of 41
Most frequent other events
EventTolvaptanPlacebo
ThirstGeneral disorders532/96199/483
PolyuriaRenal and urinary disorders369/96183/483
HypertensionVascular disorders324/961178/483
Renal painRenal and urinary disorders266/961172/483
NocturiaRenal and urinary disorders281/96163/483
HeadacheNervous system disorders243/961123/483
PollakiuriaRenal and urinary disorders222/96126/483
NasopharyngitisInfections and infestations221/961111/483
Back painMusculoskeletal and connective tissue disorders138/96190/483
Dry mouthGastrointestinal disorders154/96160/483

Baseline characteristics

Intent-to-treat population: All randomized participants.

Age, Continuous
Age, Continuous(years)TolvaptanPlaceboTotal
Mean38.6 ± 7.138.8 ± 7.138.7 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)TolvaptanPlaceboTotal
Female466233699
Male495251746
08

Study locations

133 sites
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
  • University of South Alabama
    Mobile, Alabama 36617, United States
  • Apex Research of Riverside
    Riverside, California 92503, United States
  • Stanford University Medical Center
    Stanford, California 94305-5114, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80262, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Coastal Nephrology Associates Research Center, LLC
    Port Charlotte, Florida 33952, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30308, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Renal Associates of Baton Rough, L.L.C.
    Baton Rouge, Louisiana 70809, United States
  • John Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
  • Tufts- New England Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Mayo Medical Center
    Rochester, Minnesota 55905, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Nephrology Associates of Westchester
    Hawthorne, New York 10532, United States
  • The Rogosin Institute
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of North Carolina, UNC, Kidney Center
    Chapel Hill, North Carolina 27599, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Kidney and Hypertension Center
    Cincinnati, Ohio 45220, United States
  • University Hospitals of Cleveland/Case
    Cleveland, Ohio 44106, United States
  • Northwest Renal Clinic, Inc.
    Portland, Oregon 97210, United States
  • University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Charleston Nephrology Associates
    Charleston, South Carolina 29405, United States
  • Nephrology Associates, P.C.
    Nashville, Tennessee 37205, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-1371, United States
  • University of Virginia, Nephrology Clinical Research Center
    Charlottesville, Virginia 22908, United States
  • Instituto de Nefrología, Nefrology SA
    Buenos Aires, 1425, Argentina
  • Hospital Municipal de Vicente Lopez, Dr Bernardo Houssay
    Buenos Aires, 1602, Argentina
  • Hosptial Universitario Austral
    Buenos Aires, B1664INZ, Argentina
  • Sanatorio Allende
    Cordoba, X5000IUP, Argentina
  • Hospital Privado-Centro Medico de Cordoba
    Cordoba, X5016KEA, Argentina
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
  • Queen Elizebeth Hospital
    Adelaide, 5011, Australia
  • Princess Alexandra Hospital
    Brisbane, 4102, Australia
  • Royal Melbourne Hospital
    Melbourne, 3050, Australia
  • Melbourne Renal Research Group
    Melbourne, 3121, Australia
  • Royal Perth Hospital
    Perth, 6054, Australia
  • Royal North Shore Hospital
    Sydney, 2065, Australia
  • Westmead Hospital
    Sydney, 2145, Australia
  • Ucl-St Luc
    Brussels, 1200, Belgium
  • UZ Brussel
    Brussel, 1090, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Queen Elizabeth II Health Science Center, Division of Nephrology
    Halifax, Nova Scotia B3H1v8, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A1A1, Canada
  • Hospital du Sacre- Coeur de Montreal
    Montreal, Quebec H4J1C5, Canada
  • Herlev Amtssygehus
    Herlev, 2730, Denmark
  • Odense Universitetshospital
    Odense, 5000, Denmark
  • CHU-Hopital Pellegrin
    Bordeaux, 33076, France
  • CHU - Hôpital Clémenceau
    Caen Cedex, 14033, France
  • Hôpital Edouard Herriot
    Lyon Cedex 3, 69437, France
  • Hôpital de la Conception
    Marseille, 13005, France
  • CHU - Hôpital Lapeyronie
    Montpellier, 34295, France
  • Hopital Bichat-Claude Bernard
    Paris, 75018, France
  • Centre Hospitalier Universitaire
    Reims cedex, 51092, France
  • CHU - Hôpital Nord
    Saint-Etienne Cedex 2, 42055, France
  • Hopital Rangueil
    Toulouse Cedex 09, 31059, France
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 1307, Germany
  • Nephrologische Gemeinschaftspraxis/Dialysezentrum
    Düsseldorf, 40210, Germany
  • Klinik für Nieren- und Hochdruckkrankheiten
    Essen, 45147, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 78106, Germany
  • Universitätskliniken Heidelberg
    Heidelberg, 69120, Germany
  • UH Erlangen/Nürnberg
    Nuernberg, 90471, Germany
  • Ospedali Riuniti di Bergamo
    Bergamo, 24128, Italy
  • Università Vita e Salute, Ospedale San Raffaele
    Milano, 20132, Italy
  • Policlinico di Modena
    Modena, 41100, Italy
  • Policlinico
    Napoli, 80131, Italy
  • IRCCS Fondazione Salvatore Maugeri
    Pavia, 27100, Italy
  • Fujita Health University Hospital
    Toyoake, Aichi 4701192, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 608648, Japan
  • Tokai University Hospital
    Isehara, Kanagawa 2591193, Japan
  • Toranomon Hospital Kajigaya
    Kawasaki, Kanagawa 2138587, Japan
  • Kitasato University Hospital
    Sagamihara, Kanagawa 2288555, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 9808574, Japan
  • Osaka City University Hospital
    Osaka-City, Osaka 5458586, Japan
  • Osaka University Hospital
    Suita, Osaka 5650871, Japan
  • Shuwa General Hospital
    Kasukabe, Saitama 3440035, Japan
  • Saitama Medical Center
    Kawagoe, Saitama 3508500, Japan
  • Hamamatsu University School of Medicine, University Hospital
    Hamamatsu, Shizuoka 4313192, Japan
  • Jichi Medical School Hospital
    Shimotsuke, Tochigi 3290498, Japan
  • Tokyo Medical & Dental University Hospital, Faculty of Medicine
    Bunkyo-ku, Tokyo 1138519, Japan
  • Nippon Medical School Hospital
    Bunkyo-ku, Tokyo 1138603, Japan
  • Teikyo University Hospital
    Itabashi-ku, Tokyo 1738606, Japan
  • Toranomon Hospital
    Minato-ku, Tokyo 1058470, Japan
  • The Jikei University Hospital
    Minato-Ku, Tokyo 1058471, Japan
  • Kyorin University Hospital
    Mitaka, Tokyo 1818611, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo 1628666, Japan
  • Chiba University Hospital
    Chiba, 2608677, Japan
  • National Hospital Organization Chiba-East Hospital
    Chiba, 2608712, Japan
  • Kyusyu University Hospital
    Fukuoka, 8128582, Japan
  • Fukushima Medical University Hospital
    Fukushima, 9601295, Japan
  • Hiroshima University Hospital
    Hiroshima, 7348551, Japan
  • Kumamoto Univeristy Hospital
    Kumamoto, 8608556, Japan
  • Kyoto University Hospital
    Kyoto, 6068507, Japan
  • National Hospital Organization Kyoto Medical Center
    Kyoto, 612-8555, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, 9518520, Japan
  • Ohno Memorial Hospital
    Osaka, 5500015, Japan

Showing the first 100 of 133 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oct;9(10):1323-6. doi: 10.1038/nm935. Epub 2003 Sep 21. PubMed 14502283 ↗
  • Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004 Apr;10(4):363-4. doi: 10.1038/nm1004. Epub 2004 Feb 29. PubMed 14991049 ↗
  • Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17. PubMed 21333426 ↗
  • Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. PubMed 23121377 ↗
  • Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3. PubMed 26188764 ↗
  • Kher A. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1257-8. doi: 10.1056/NEJMc1300762. No abstract available. PubMed 23534570 ↗
  • Spital A. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1257. doi: 10.1056/NEJMc1300762. No abstract available. PubMed 23534569 ↗
  • Torres VE, Gansevoort RT, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1259. doi: 10.1056/NEJMc1300762. No abstract available. PubMed 23534568 ↗
  • Jouret F, Krzesinski JM. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1258-9. doi: 10.1056/NEJMc1300762. No abstract available. PubMed 23534572 ↗
  • Sexton DJ. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1258. doi: 10.1056/NEJMc1300762. No abstract available. PubMed 23534571 ↗
  • Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. doi: 10.2215/CJN.16871020. Epub 2021 Jun 11. PubMed 34117082 ↗
  • Heida JE, Gansevoort RT, Torres VE, Devuyst O, Perrone RD, Lee J, Li H, Ouyang J, Chapman AB. The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. J Am Soc Nephrol. 2021 Jul;32(7):1801-1812. doi: 10.1681/ASN.2020101512. Epub 2021 Apr 22. PubMed 33888577 ↗
  • Bennett H, McEwan P, Hamilton K, O'Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5. PubMed 31014270 ↗
  • McEwan P, Bennett Wilton H, Ong ACM, Orskov B, Sandford R, Scolari F, Cabrera MV, Walz G, O'Reilly K, Robinson P. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol. 2018 Feb 13;19(1):37. doi: 10.1186/s12882-017-0804-2. PubMed 29439650 ↗
  • Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043. PubMed 28379536 ↗
  • Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015 Oct;19(5):867-77. doi: 10.1007/s10157-015-1086-2. Epub 2015 Feb 7. PubMed 25663351 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 5 years 6 months after primary completion. A results delay was requested in Feb 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2007
First posted
Jan 30, 2007
Start
Jan 2007
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results delay requested
Feb 1, 2013
Results first posted
Jul 2, 2017
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00428948
Responsible party
Sponsor
First posted
Jan 30, 2007
Start date
Jan 2007
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jul 2, 2017
Last update
Jul 2, 2017

Study contacts

Vicente Torres, MD, PhD
principal investigator · Mayo Medical Center
Frank Czerwiec, MD, PhD
study director · Otsuka Pharmaceutical Development and Commercialization, Inc.
Osamu Sato
study director · Otsuka Pharmaceutical Corporation, Ltd. Japan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion